CHRISTOPHER FORBES Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for CHRISTOPHER FORBES.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of CHRISTOPHER FORBES. CHRISTOPHER FORBES is Director in Sevion Therapeutics, Inc. ($SVON).
Latest Insider Trading Transactions of CHRISTOPHER FORBES
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 19 2011 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.30 | 37,962 | 11,389 | 741,239 | |
Mar 23 2011 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.28 | 15,000 | 4,191 | 7,452,289 | 7.4 M to 7.5 M (+0.20 %) |
Feb 16 2011 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.32 | 32,758 | 10,483 | 703,277 | |
Nov 19 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.29 | 67,308 | 19,519 | 670,519 | |
Nov 19 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.29 | 125,000 | 36,250 | 603,211 | |
Jun 03 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 0.32 | 1,000 | 320 | 1,000 | |
Jun 03 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 0.35 | 3,125,000 | 1,093,750 | 7,091,477 | |
May 27 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | C | 0.83 | 4,101,800 | 3,404,494 | 7,407,289 | 3.3 M to 7.4 M (+124.09 %) |
May 27 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Grant | A | 0.51 | 78,469 | 40,294 | 3,305,489 | 3.2 M to 3.3 M (+2.43 %) |
May 27 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Grant | A | 0.37 | 182,840 | 67,157 | 3,227,020 | 3 M to 3.2 M (+6.01 %) |
May 24 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.67 | 19,262 | 12,906 | 478,211 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.32 | 54,166 | 17,333 | 458,949 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 0.83 | 567,416 | 470,955 | 3,966,477 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 0.83 | 851,123 | 706,432 | 3,399,061 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 1.01 | 567,416 | 573,090 | 2,547,938 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 1.01 | 851,123 | 859,634 | 1,980,522 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | P | 1.01 | 510,676 | 515,783 | 1,129,399 | |
Feb 23 2010 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.00 | 882,381 | 0 | 3,044,180 | 2.2 M to 3 M (+40.82 %) |
Nov 23 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.43 | 40,000 | 17,200 | 404,783 | |
Nov 23 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.43 | 48,718 | 20,949 | 364,783 | |
Nov 23 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.65 | 18,077 | 11,750 | 316,065 | |
Jul 31 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.00 | 89,222 | 0 | 618,723 | 529.5 K to 618.7 K (+16.85 %) |
Jul 31 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.00 | 88,000 | 0 | 529,501 | 441.5 K to 529.5 K (+19.93 %) |
Jul 31 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.90 | 97,778 | 88,000 | 2,191,799 | 2.1 M to 2.2 M (+4.67 %) |
Mar 17 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.51 | 200 | 102 | 2,094,021 | 2.1 M to 2.1 M (+0.01 %) |
Mar 17 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.49 | 2,300 | 1,127 | 2,093,821 | 2.1 M to 2.1 M (+0.11 %) |
Mar 17 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.46 | 2,300 | 1,058 | 2,091,521 | 2.1 M to 2.1 M (+0.11 %) |
Mar 16 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.39 | 10,200 | 3,978 | 2,089,221 | 2.1 M to 2.1 M (+0.49 %) |
Mar 16 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.36 | 2,000 | 720 | 2,079,021 | 2.1 M to 2.1 M (+0.10 %) |
Mar 11 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.37 | 2,500 | 925 | 2,077,021 | 2.1 M to 2.1 M (+0.12 %) |
Mar 11 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.38 | 10,000 | 3,800 | 2,074,521 | 2.1 M to 2.1 M (+0.48 %) |
Mar 06 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.40 | 1,000 | 400 | 2,064,521 | 2.1 M to 2.1 M (+0.05 %) |
Mar 06 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.38 | 2,000 | 760 | 2,063,521 | 2.1 M to 2.1 M (+0.10 %) |
Mar 06 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.40 | 5,500 | 2,200 | 2,061,521 | 2.1 M to 2.1 M (+0.27 %) |
Mar 04 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.40 | 1,200 | 480 | 2,056,021 | 2.1 M to 2.1 M (+0.06 %) |
Mar 04 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.39 | 3,000 | 1,170 | 2,054,821 | 2.1 M to 2.1 M (+0.15 %) |
Mar 04 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.37 | 2,800 | 1,036 | 2,051,821 | 2 M to 2.1 M (+0.14 %) |
Mar 02 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.39 | 2,000 | 780 | 2,049,021 | 2 M to 2 M (+0.10 %) |
Mar 02 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.40 | 3,000 | 1,200 | 2,047,021 | 2 M to 2 M (+0.15 %) |
Mar 02 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.40 | 4,000 | 1,600 | 2,044,021 | 2 M to 2 M (+0.20 %) |
Feb 24 2009 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.52 | 23,404 | 12,170 | 337,988 | |
Dec 17 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.70 | 2,000 | 1,400 | 2,040,021 | 2 M to 2 M (+0.10 %) |
Dec 17 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.74 | 2,000 | 1,480 | 2,040,021 | 2 M to 2 M (+0.10 %) |
Dec 16 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.70 | 3,000 | 2,100 | 2,036,021 | 2 M to 2 M (+0.15 %) |
Dec 16 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.61 | 2,900 | 1,769 | 2,036,021 | 2 M to 2 M (+0.14 %) |
Dec 16 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.60 | 100 | 60 | 2,036,021 | 2 M to 2 M (0.00 %) |
Dec 16 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Buy | P | 0.60 | 4,000 | 2,400 | 2,036,021 | 2 M to 2 M (+0.20 %) |
Nov 21 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.66 | 50,000 | 33,000 | 300,000 | |
Nov 21 2008 | SVON | Sevion Therapeutic ... | FORBES CHRISTOPHER | Director | Option Exercise | A | 0.66 | 14,584 | 9,625 | 314,584 |
Page: 1